🇺🇸 FDA

Intelligence · Clinical Pipeline

Anaxis Pharma Pipeline

All ClinicalTrials.gov programs at Anaxis Pharma — phase, modality, and trial IDs.

Programs
642

Quick answer

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

    Lacuna Pharma Pty Ltd

    Geographic Atrophy

    phase 1 other active

    1 trial

  2. JR-441

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type IIIA (MPS IIIA)

    phase 1 small molecule active

    1 trial

  3. METRONIDAZOLE, MOLGRAMOSTIM, Saline Solution Basi 9 mg/ml solution for infusion, FOSFOMYCIN

    Lacuna Pharma Pty Ltd

    peritonitis

    phase 1 small molecule active

    1 trial

  4. Methotrexate PK (in combination with Novobiocin) in RA patients

    Lacuna Pharma Pty Ltd

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  5. Minzasolmin, UCB0599 PRD4385815

    Lacuna Pharma Pty Ltd

    Healthy Participants

    phase 1 small molecule active

    1 trial

  6. NXP800 in subjects with Ovarian Cancer

    Lacuna Pharma Pty Ltd

    Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinoma

    phase 1 other active

    1 trial

  7. OMTX705-006 Phase 1b

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  8. Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence study)

    phase 1 other active

    1 trial

  9. PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial

    Lacuna Pharma Pty Ltd

    Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

    phase 1 other active

    1 trial

  10. PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

    Lacuna Pharma Pty Ltd

    relapsed/refractory hematologic malignancies

    phase 1 other active

    1 trial

  11. Paracetamol 1000mg Tablets, Diphenhydramin-Hevert Injektionslösung, Diphenhydramine Hydrochloride Tablets 25 mg, LYNOZYFIC 200 mg concentrate for solution for infusion, LYNOZYFIC 5 mg concentrate for solution for infusion, Dexamethasone 3.3 mg/ml solution for injection/infusion, REGN17372

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 1 small molecule active

    1 trial

  12. Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants

    Lacuna Pharma Pty Ltd

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    phase 1 other active

    1 trial

  13. Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults.

    Lacuna Pharma Pty Ltd

    Healthy Volunteer

    phase 1 other active

    1 trial

  14. Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults.

    Lacuna Pharma Pty Ltd

    Healthy Volunteers

    phase 1 other active

    1 trial

  15. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  16. Phase I Study of PM54 Administered to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Selected Advanced Solid Tumors

    phase 1 other active

    1 trial

  17. Phase I Study of Plitidepsin Administered Intravenously as a Single Dose in Healthy Volunteers

    Lacuna Pharma Pty Ltd

    Virus diseases

    phase 1 other active

    1 trial

  18. Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy participants.

    Lacuna Pharma Pty Ltd

    Androgenetic alopecia

    phase 1 other active

    1 trial

  19. Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced solid tumors

    phase 1 other active

    1 trial

  20. Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)

    Lacuna Pharma Pty Ltd

    Immune-mediated necrotizing myopathy, Antiphospholipid syndrome, Behçet’s Syndrome, Bullous pemphigoid, Dermatomyositis, Immune Thrombocytopenia

    phase 1 other active

    1 trial

  21. Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 1 other active

    1 trial

  22. Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

    Lacuna Pharma Pty Ltd

    Bullous pemphigoid, Behçet’s Syndrome, Dermatomyositis, Antiphospholipid syndrome, Immune-mediated necrotizing myopathy, Immune Thrombocytopenia

    phase 1 other active

    1 trial

  23. Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients with Parkinson’s Disease

    Lacuna Pharma Pty Ltd

    Parkinson’s Disease

    phase 1 other active

    1 trial

  24. RANDOMISED, CROSSOVER, SIMPLE-BLINDED, BIOEQUIVALENCE CLINICAL TRIAL OF ALMOTRIPTAN 12.5 MG ORODISPERSIBLE TABLETS VERSUS ALMOTRIPTAN 12.5 MG FILM-COATED TABLETS, AFTER A SINGLE ORAL DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS UNDER FASTING

    Lacuna Pharma Pty Ltd

    Antimigraine

    phase 1 other active

    1 trial

  25. Randomised, relative bioavailability clinical trial of amylmetacresol, dichlorobenzyl alcohol, lidocaine and vitamin c lozenges after a single oral dose administration to healthy volunteers under fasting conditions in a crossover design.

    Lacuna Pharma Pty Ltd

    healthy volunteer

    phase 1 other active

    1 trial

  26. Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.

    Lacuna Pharma Pty Ltd

    Comparative bioavailability study under fasting conditions

    phase 1 other active

    1 trial

  27. Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is bioavailability)

    phase 1 other active

    1 trial

  28. Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsalicylic acid, tablet, 2.5 mg/50 mg (given as two tablets) to reference product Xarelto 2.5 mg film-coated tablets (given as two tablets) and Aspirin® N 100 mg tablet in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial

  29. Repomol, Metronidazol ”Baxter” Viaflo, infusionsvæske, opløsning, Saline Solution Basi 9 mg/ml solution for infusion, Fosfomycin "Infectopharm", pulver til infusionsvæske, opløsning 40 mg/ml

    Lacuna Pharma Pty Ltd

    peritonitis

    phase 1 small molecule active

    1 trial

  30. SPECT/CT imaging of FPI-2505 in patients with solid tumours; a phase 0 molecular imaging basket trial (SCOPE-study).

    Lacuna Pharma Pty Ltd

    small cell lung cancer, non-smallcell lung cancer, colorectal cancer, breast cancer, Pancreatic cancer and gastric cancer

    phase 1 other active

    1 trial

  31. Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma

    Lacuna Pharma Pty Ltd

    Glaucoma

    phase 1 other active

    1 trial

  32. Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

  33. Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Allergy

    Lacuna Pharma Pty Ltd

    Severe IgE-mediated food allergy

    phase 1 other active

    1 trial

  34. Single dose oral bioequivalence study of Cladribine 10 mg Tablets and Mavenclad® 10 mg tablets (Cladribine) in healthy adult human subjects under fed conditions

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  35. Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

    Lacuna Pharma Pty Ltd

    Squamous Cell Carcinoma of Head and Neck

    phase 1 other active

    1 trial

  36. Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 1 other active

    1 trial

  37. TGD001 SAD study in healthy volunteers

    Lacuna Pharma Pty Ltd

    A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers

    phase 1 other active

    1 trial

  38. Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)

    phase 1 small molecule active

    1 trial

  39. The clinical trial to study a new drug, AP-2.

    Lacuna Pharma Pty Ltd

    ALS and related disorders like frontotemporal dementia and Alexander disease.

    phase 1 other active

    1 trial

  40. The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory B-cell Lymphoma

    phase 1 other active

    1 trial

  41. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  42. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.

    Lacuna Pharma Pty Ltd

    influenza

    phase 1 other active

    1 trial

  43. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adult patients.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  44. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adults patients.

    Lacuna Pharma Pty Ltd

    Bioequivalence study under fasting conditions

    phase 1 other active

    1 trial

  45. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects.

    phase 1 other active

    1 trial

  46. This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Inducible Urticaria (CIndU) to assess if it is safe and improves reactions to known CIndU triggers.

    Lacuna Pharma Pty Ltd

    Chronic Inducible Urticaria

    phase 1 other active

    1 trial

  47. Treatment of Respiratory Complications Associated with COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus (RSV) Infection Using Wharton’s Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): open Phase IB Clinical Trial

    Lacuna Pharma Pty Ltd

    Respiratory viral disease, COVID-19, Influenza A, Metapneumovirus, Respiratory syncytial virus Infection

    phase 1 other active

    1 trial

  48. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

Frequently asked questions

How many pipeline programs does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.